TER Teradyne

Q3 2025 10-Q

Filed: Oct 30, 2025Period ending Sep 28, 2025

Health Care

Instruments For Meas & Testing of Electricity & Elec SignalsSEC EDGAR

Teradyne (TER) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 28, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $769.2M Q3 2025, up 4.3% YoY from $737.3M; Semiconductor Test $605.9M (+6.6%), Product Test $88.3M (+10.2%), Robotics $75.1M (-15.3%)
• Gross margin 58.4% Q3 2025 vs 59.2% Q3 2024; 9-month gross margin 58.7% vs 58.1% YoY

+3 more insights

Risk Factors

• No new risk factors added or updated since 10-K filed February 20, 2025
• Carried-forward market risk: supply chain disruptions impacting component availability and lead times

+2 more insights

Quarterly Financial Summary
XBRL

Revenue

$769M

Net Income

$120M

Net Margin

15.5%

Source: XBRL data from Teradyne Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Teradyne Quarterly Reports

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Teradyne

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.